CA1307740C - Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus - Google Patents
Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virusInfo
- Publication number
- CA1307740C CA1307740C CA000543641A CA543641A CA1307740C CA 1307740 C CA1307740 C CA 1307740C CA 000543641 A CA000543641 A CA 000543641A CA 543641 A CA543641 A CA 543641A CA 1307740 C CA1307740 C CA 1307740C
- Authority
- CA
- Canada
- Prior art keywords
- dextran sulphate
- htlv
- iii
- pharmaceutical preparation
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 19
- 230000010076 replication Effects 0.000 title claims abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
- 230000002401 inhibitory effect Effects 0.000 title claims description 9
- 238000000034 method Methods 0.000 title description 5
- 229920002307 Dextran Polymers 0.000 claims abstract description 31
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 30
- 229910021653 sulphate ion Inorganic materials 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 208000030507 AIDS Diseases 0.000 claims abstract description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000005864 Sulphur Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 3
- 230000001066 destructive effect Effects 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 235000009529 zinc sulphate Nutrition 0.000 description 2
- 239000011686 zinc sulphate Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229920001448 anionic polyelectrolyte Polymers 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- WRSZRYQLLVUDNG-UHFFFAOYSA-N formamide;sulfurochloridic acid Chemical compound NC=O.OS(Cl)(=O)=O WRSZRYQLLVUDNG-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT
Dextran sulphate and salts thereof are used to inhibit replication of HTLV-III (AIDS) virus both in vivo and in vitro. The same compounds are used in solution to inhibit the destructive action of HTLV-III virus upon human lymphocyte T helper cells.
Preferably the dextran sulphate or salts thereof have a molecular weight in the range of 3000-500,000 and a sulphur content of 12-25%.
Dextran sulphate and salts thereof are used to inhibit replication of HTLV-III (AIDS) virus both in vivo and in vitro. The same compounds are used in solution to inhibit the destructive action of HTLV-III virus upon human lymphocyte T helper cells.
Preferably the dextran sulphate or salts thereof have a molecular weight in the range of 3000-500,000 and a sulphur content of 12-25%.
Description
13077~0 This invention relates to a pharmaceutical preparation and method for inhibiting replication of HTLV-III (AIDS) Virus.
Certain retrovirus infections have been known to depress immune functions in animals. In recent years it has been discovered that a family of T-lymphotropic retroviruses causes T-cell proliferation leukemia, helper T-cell depletion, and immunosuppression in humans infected by these viruses. These viruses have become known as the HTLV family of retroviruses. A
group of these viruses designated as HTLV-III has been isolated from patients with acquired immune deficiency syndrome (AIDS) and has become considered to be responsible for the development of this condition in humans.
A cell line representative of this group has been deposited under ATCC No. CRL8543 by an agency of the U.S. Department of Health and Human Services.
Up to the present there has been no effective treatment for the damage to the human immune system created by the infection with this virus, although certain drugs have been shown to have some inhibitory effects upon replication. These effects are not cumulative and appear to be of temporary duration.
One of such drugs is azidothymidine (AZT) which has the disadvantage of numerous serious side effects, especially with long term usage.
~3()7740 Dextran Sulphate is a product obtained by methods well known to the art, such as by sulfation of dextran with chlorsulfonic acid in pyridine (Ricketts, Biochem J. 51 210-233 -1952) or by means of concentrated sulphuric acid (U.S. Patent No.
3,498,972) or by chlorsulfonic acid - formamide (U.S. Patent No.
3,141,014), etc.
Sodium dextran sulphate ~M.W. 7000-8000) has been utilized as an anticoagulant and has been in chemical use in Japan as an anti lipaemic agent for more than 20 years and has been proven safe for human use by oral administration over long term use.
Dextran sulphate of higher molecular weights has been found to be useful in the treatment of peptic ulcers as an oral drug and by in;ection for the treatment of Scrapie infection in animals.
Applicant has now determined that dextran sulphate and its salts, particularly the sodium salt thereof, can inhibit the replication of HTLV-III virus in vitro and in vivo, particularly in proper concentrations and in suitable molecular weights, depending on whether topical, oral or intravenous application is desired.
Accordingly, the present invention comprises a pharmaceutical preparation for inhibiting replication of HTLV-III virus which comprises a compound selected from the class consisting of dextran sulphate and the salts thereof.
B
13~7740 This invention provides for both a method of making and an antiviral pharmaceutical composition comprising dextran sulphate or its salts in admixture with a pharmaceutically acceptable diluant or carrier suitable for topical use. Examples of such diluants or carriers are white petrolatum, Glaxaltm base and Unibasetm. The diluant or carrier may have a water base or an oil base. The topical formulation of the antiviral composition of the present invention may be a suspension, an emulsion, a power, an ointment, a cream or other suitable topical formulation.
- 2a -jm7-3363d53 This invention further provides for both a method of making and an antiviral pharmaceutical composition comprising dextran sulphate or its salts in admixture with a pharmaceutically acceptable diluant or carrier suitable for intravenous use.
Examples of such diluants or carriers are normal saline and dextrose solution.
This invention still further provides for both a method of making and an antiviral pharmaceutical composition comprising dextran sulphate or its salts in admixture with a pharmaceutically acceptable diluant or carrier suitable for oral use. Examples of such diluants or carriers are lactose, dextrose and starch.
The antiviral composition (and method for making same) of the present invention may also include zinc sulphate which has a synergistic effect on dextran sulphate and its salts. The proportion of zinc sulphate to dextran sulphate or its salts may be in the ratio of 5-10:1 respectively.
Since dextran sulphate and its salts having molecular weights in the range of 3000-40,000 are systematically absorbed they may be utilized by oral administration. Higher molecular weights up to about 500,000 or more may be utilized by injection. Sulphur content may range from 12-25%.
In evaluating the effectiveness of dextran sulphate, the following test procedures have been carried out.
Human T-lymphocyte cells were exposed to HTLV-III cells in jm7-3363d53 culture and almost all cells were destroyed by the end of the sixth day. Dextran sulphate (8,000 M.W. sulphur content 18%) was then added to another sample of same human T-cell culture in the proportion of 10 micrograms per milliliter. This sample was then inoculated with HTLV-III cells and allowed to stand. On the sixth day the target lymphocyte cells wera counted and found to be essentially unaffected by the virus and continued to proliferate thereafter. This clearly indicated substantially complete blockage of the viral toxicity of HTLV-III. Although this procedure was carried out in vitro, similar in vivo activity can be predicted.
Based upon prior studies relating to the action of anionic polyelectrolyte drugs upon other types of viruses, it would appear that the effectiveness of dextran sulphate upon this HTLV-III virus stems from one or more of several different types of activity. The inhibiting effect may be due to the fact that studies have shown that dextran sulphate markedly enhances aggregation of virus cells and thus can inhibit absorption and penetration into target cells.
Dextran sulphate and other similar polyelectrolytes tend to complex with proteins and hence may react to a certain extent with the cell walls of the virus to impair their activity. In addition, prior data indicates that injections of high molecular weight dextran sulphate appear to increase immune response and the production in target cells of a viral inhibitor having interferon-like activity.
13077~0 jm7-3363d53 For use with animals, including human use, the selected dextran sulphate or sodium salt thereof may be formulated in known conventional manner into tablets or capsules for oral administration, ointments and creams for topical application or may be prepared in solution or suspension for injection. Dosage requirements for animal or human use based upon the above data indicate that administration of 1-5 grams daily would be sufficient to produce the desired blood levels of dextran sulphate to produce inhibition. Such dosages have been found to be safe for long term use.
Certain retrovirus infections have been known to depress immune functions in animals. In recent years it has been discovered that a family of T-lymphotropic retroviruses causes T-cell proliferation leukemia, helper T-cell depletion, and immunosuppression in humans infected by these viruses. These viruses have become known as the HTLV family of retroviruses. A
group of these viruses designated as HTLV-III has been isolated from patients with acquired immune deficiency syndrome (AIDS) and has become considered to be responsible for the development of this condition in humans.
A cell line representative of this group has been deposited under ATCC No. CRL8543 by an agency of the U.S. Department of Health and Human Services.
Up to the present there has been no effective treatment for the damage to the human immune system created by the infection with this virus, although certain drugs have been shown to have some inhibitory effects upon replication. These effects are not cumulative and appear to be of temporary duration.
One of such drugs is azidothymidine (AZT) which has the disadvantage of numerous serious side effects, especially with long term usage.
~3()7740 Dextran Sulphate is a product obtained by methods well known to the art, such as by sulfation of dextran with chlorsulfonic acid in pyridine (Ricketts, Biochem J. 51 210-233 -1952) or by means of concentrated sulphuric acid (U.S. Patent No.
3,498,972) or by chlorsulfonic acid - formamide (U.S. Patent No.
3,141,014), etc.
Sodium dextran sulphate ~M.W. 7000-8000) has been utilized as an anticoagulant and has been in chemical use in Japan as an anti lipaemic agent for more than 20 years and has been proven safe for human use by oral administration over long term use.
Dextran sulphate of higher molecular weights has been found to be useful in the treatment of peptic ulcers as an oral drug and by in;ection for the treatment of Scrapie infection in animals.
Applicant has now determined that dextran sulphate and its salts, particularly the sodium salt thereof, can inhibit the replication of HTLV-III virus in vitro and in vivo, particularly in proper concentrations and in suitable molecular weights, depending on whether topical, oral or intravenous application is desired.
Accordingly, the present invention comprises a pharmaceutical preparation for inhibiting replication of HTLV-III virus which comprises a compound selected from the class consisting of dextran sulphate and the salts thereof.
B
13~7740 This invention provides for both a method of making and an antiviral pharmaceutical composition comprising dextran sulphate or its salts in admixture with a pharmaceutically acceptable diluant or carrier suitable for topical use. Examples of such diluants or carriers are white petrolatum, Glaxaltm base and Unibasetm. The diluant or carrier may have a water base or an oil base. The topical formulation of the antiviral composition of the present invention may be a suspension, an emulsion, a power, an ointment, a cream or other suitable topical formulation.
- 2a -jm7-3363d53 This invention further provides for both a method of making and an antiviral pharmaceutical composition comprising dextran sulphate or its salts in admixture with a pharmaceutically acceptable diluant or carrier suitable for intravenous use.
Examples of such diluants or carriers are normal saline and dextrose solution.
This invention still further provides for both a method of making and an antiviral pharmaceutical composition comprising dextran sulphate or its salts in admixture with a pharmaceutically acceptable diluant or carrier suitable for oral use. Examples of such diluants or carriers are lactose, dextrose and starch.
The antiviral composition (and method for making same) of the present invention may also include zinc sulphate which has a synergistic effect on dextran sulphate and its salts. The proportion of zinc sulphate to dextran sulphate or its salts may be in the ratio of 5-10:1 respectively.
Since dextran sulphate and its salts having molecular weights in the range of 3000-40,000 are systematically absorbed they may be utilized by oral administration. Higher molecular weights up to about 500,000 or more may be utilized by injection. Sulphur content may range from 12-25%.
In evaluating the effectiveness of dextran sulphate, the following test procedures have been carried out.
Human T-lymphocyte cells were exposed to HTLV-III cells in jm7-3363d53 culture and almost all cells were destroyed by the end of the sixth day. Dextran sulphate (8,000 M.W. sulphur content 18%) was then added to another sample of same human T-cell culture in the proportion of 10 micrograms per milliliter. This sample was then inoculated with HTLV-III cells and allowed to stand. On the sixth day the target lymphocyte cells wera counted and found to be essentially unaffected by the virus and continued to proliferate thereafter. This clearly indicated substantially complete blockage of the viral toxicity of HTLV-III. Although this procedure was carried out in vitro, similar in vivo activity can be predicted.
Based upon prior studies relating to the action of anionic polyelectrolyte drugs upon other types of viruses, it would appear that the effectiveness of dextran sulphate upon this HTLV-III virus stems from one or more of several different types of activity. The inhibiting effect may be due to the fact that studies have shown that dextran sulphate markedly enhances aggregation of virus cells and thus can inhibit absorption and penetration into target cells.
Dextran sulphate and other similar polyelectrolytes tend to complex with proteins and hence may react to a certain extent with the cell walls of the virus to impair their activity. In addition, prior data indicates that injections of high molecular weight dextran sulphate appear to increase immune response and the production in target cells of a viral inhibitor having interferon-like activity.
13077~0 jm7-3363d53 For use with animals, including human use, the selected dextran sulphate or sodium salt thereof may be formulated in known conventional manner into tablets or capsules for oral administration, ointments and creams for topical application or may be prepared in solution or suspension for injection. Dosage requirements for animal or human use based upon the above data indicate that administration of 1-5 grams daily would be sufficient to produce the desired blood levels of dextran sulphate to produce inhibition. Such dosages have been found to be safe for long term use.
Claims (8)
1. A pharmaceutical preparation for inhibiting replication of HTLV-III virus which comprises a compound selected from the class consisting of dextran sulphate and the salts thereof.
2. A pharmaceutical preparation according to claim 1, comprising sodium dextran sulphate.
3. A pharmaceutical preparation for inhibition of activity of HTLV-III virus which comprises dextran sulphate or its salts having a molecular weight in the range of 3000-500,000 and a sulphur content of 12-15%.
4. A pharmaceutical preparation for inhibiting the destructive action of HTLV-III or "AIDS" virus upon human lymphocyte T-helper cells which comprises a pharmaceutically acceptable formulation comprising dextran sulphate or salts thereof.
5. A pharmaceutical preparation according to claim 4 which comprises sodium dextran sulphate.
6. A pharmaceutical preparation for inhibiting replication of HIV viruses such as HTLV-III which comprises a compound selected from the class consisting of dextran sulphate and the salts thereof.
7. A pharmaceutical composition for inhibiting replication of HTLV-III virus by oral administration comprising:
an active ingredient selected from the group of dextran sulphate and salts of dextran sulphate; and a pharmaceutically acceptable carrier for oral administration.
an active ingredient selected from the group of dextran sulphate and salts of dextran sulphate; and a pharmaceutically acceptable carrier for oral administration.
8. The pharmaceutical preparation according to claim 7 wherein said active ingredient is the sodium salt of dextran sulphate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000543641A CA1307740C (en) | 1987-08-05 | 1987-08-05 | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000543641A CA1307740C (en) | 1987-08-05 | 1987-08-05 | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1307740C true CA1307740C (en) | 1992-09-22 |
Family
ID=4136200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000543641A Expired - Lifetime CA1307740C (en) | 1987-08-05 | 1987-08-05 | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1307740C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006003521A1 (en) * | 2004-02-06 | 2006-01-12 | Monash University | High dose, short interval use of sulfated polysaccharides for the treatment of infections |
-
1987
- 1987-08-05 CA CA000543641A patent/CA1307740C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006003521A1 (en) * | 2004-02-06 | 2006-01-12 | Monash University | High dose, short interval use of sulfated polysaccharides for the treatment of infections |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69023748T2 (en) | Use of nitrogen-containing macrocycles to treat retroviral infections. | |
| Sarin et al. | Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone | |
| KR100638684B1 (en) | 9-deoxy-2 ', 9-alpha-methano-3-oxa-4,5,6-trinor-3,7- (1', 3'-interphenylene) for the treatment of peripheral vascular disease Use of -13,14-dihydro-prostaglandin F1 | |
| US6001826A (en) | Chemical compounds | |
| US5565448A (en) | Medicament | |
| Grewal | Pharmacology of 8-aminoquinolines | |
| MD1688F2 (en) | Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection | |
| TNSN90021A1 (en) | PROCESS FOR THE PREPARATION OF TETRAHYDROIMIDAZO (1,4) BENZODIAZEPIN -2- ANTIVIRAL THIONES | |
| HU201672B (en) | Process for producing pharmaceutical compositions comprising podophyllotoxin | |
| TNSN89039A1 (en) | TETRAHYDROIMIDAZO (1,4) BENZODIAZEPIN-2-ONES ANTIVIRALS | |
| JPH072663A (en) | Virus infection remedy | |
| US5616577A (en) | Protein Kinase C inhibitor | |
| CA1307740C (en) | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus | |
| US4978687A (en) | Anti-viral agent | |
| US4892876A (en) | Method for inhibiting HIV and an pharmaceutical composition therefor | |
| CA2193396A1 (en) | A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof | |
| DE3885798T2 (en) | Protein-containing polysaccharide for the treatment of retroviral infections. | |
| Eagle et al. | The protective action of BAL in experimental antimony poisoning | |
| WO1994003169A1 (en) | Mixture of a free radical scavenger and an iron chelator for the treatment of sickle cell disease | |
| US5534523A (en) | Anti-aids virus composition | |
| NZ205587A (en) | Composition comprising undecylenic acid for treating herpes simplex i | |
| KR100227095B1 (en) | Anti-hiv agent | |
| CA1306694C (en) | Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus | |
| DK167148B1 (en) | COMPLEXES OF SELENE AND TELLUR ETHYLENDIOXY DERIVATIVES, PHARMACEUTICAL PREPARATIONS THEREOF AND APPLICATION OF THE COMPLEXES FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS | |
| KR0124028B1 (en) | Use of prolylendopeptidase inhibitors in the treatment of aids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |